Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1 beta Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features.
ARTHRITIS AND RHEUMATISM（2011）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined